Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-306,800
Closed -$8.88M 3271
2024
Q3
$8.88M Buy
306,800
+21,200
+7% +$618K 0.02% 562
2024
Q2
$7.99M Sell
285,600
-113,400
-28% -$3.12M 0.02% 596
2024
Q1
$11.1M Buy
399,000
+9,300
+2% +$258K 0.02% 461
2023
Q4
$11.2M Buy
389,700
+296,000
+316% +$8.95M 0.02% 557
2023
Q3
$3.11M Buy
+93,700
New +$3.31M 0.01% 1213

Other funds holding PFE

GTS Securities's PFE Position: Q2 2026 in Review

GTS Securities reduced its Pfizer (PFE) stake by 2.8% in Q2 2026, selling an estimated $10.5K and leaving 14,176 shares worth $341K. The position accounts for 0.01% of the portfolio, ranked #912.

GTS Securities first reported a position in PFE in Q2 2023 and has held it in 12 quarters since. The position peaked at $41.8M in Q4 2023. 2,835 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • GTS Securities held 14,176 shares of Pfizer worth $341K as of Q2 2026.
  • GTS Securities sold 403 Pfizer shares in Q2 2026, an estimated $10.5K.
  • Pfizer made up 0.01% of GTS Securities's portfolio in Q2 2026, its #912 holding.
  • GTS Securities first reported a position in Pfizer in Q2 2023 and has held it in 12 quarters since.
  • GTS Securities's Pfizer position peaked at $41.8M in Q4 2023.
  • 2,835 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.